Brokerages Set GeoVax Labs Inc. (NASDAQ:GOVX) Target Price at $11.10

GeoVax Labs Inc. (NASDAQ:GOVX) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.10.

A number of research analysts have commented on the company. Wall Street Zen upgraded GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Saturday, June 21st. Alliance Global Partners cut their price target on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research note on Tuesday, April 15th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Wednesday, April 16th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of GeoVax Labs in a research note on Monday, June 16th.

GeoVax Labs Price Performance

NASDAQ GOVX opened at $0.95 on Tuesday. The firm has a market cap of $14.43 million, a PE ratio of -0.26 and a beta of 3.45. GeoVax Labs has a one year low of $0.73 and a one year high of $11.18. The stock’s 50 day simple moving average is $1.00 and its 200 day simple moving average is $1.49.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.14. The business had revenue of $1.64 million for the quarter, compared to analyst estimates of $0.75 million. GeoVax Labs had a negative return on equity of 511.96% and a negative net margin of 438.20%. As a group, equities analysts expect that GeoVax Labs will post -4.49 earnings per share for the current year.

Institutional Trading of GeoVax Labs

Several hedge funds and other institutional investors have recently modified their holdings of GOVX. Jane Street Group LLC acquired a new stake in shares of GeoVax Labs in the 1st quarter valued at about $27,000. Northern Trust Corp acquired a new position in shares of GeoVax Labs during the 4th quarter worth approximately $29,000. Citadel Advisors LLC bought a new stake in shares of GeoVax Labs during the 4th quarter worth approximately $104,000. Geode Capital Management LLC boosted its holdings in shares of GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the last quarter. Finally, Armistice Capital LLC bought a new position in shares of GeoVax Labs in the first quarter valued at $703,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.